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Integrating first-line treatment options into clinical practice:
what’s new in advanced melanoma?
Reinhard Dummera, Dirk Schadendorfb, Paolo A. Asciertod, James Larkine,
Celeste Lebbéf and Axel Hauschildc
Melanoma remains a serious form of skin cancer in Europe
and worldwide. Localized, early-stage melanomas can
usually be treated with surgical excision. However, the
prognosis is poorer for patients with advanced disease.
Before 2011, treatment for advanced melanoma included
palliative surgery and/or radiotherapy, and chemotherapy
with or without immunotherapy, such as interleukin-2. As
none of these treatments had shown survival benefits in
patients with advanced melanoma, European guidelines
had recommended that patients be entered into clinical
trials. The lack of approved first-line options and varying
access to clinical trials meant that European clinicians
relied on experimental regimens and chemotherapy-based
treatments when no other options were available. Since
2011, ipilimumab, an immuno-oncology therapy, and
vemurafenib and dabrafenib, targeted agents that inhibit
mutant BRAF, have been approved by the European
Medicines Agency for the treatment of advanced melanoma.
More recently, the MEK inhibitor, trametinib, received
European marketing authorization for use in patients with
BRAF mutation-positive advanced melanoma. In 2014, the
anti-PD-1 antibody nivolumab was approved as a first-line
therapy in Japan. Whereas nivolumab and another anti-PD-1
antibody, pembrolizumab, were approved as second-line
therapies in the USA, their recent approval in Europe are for
first-line use based on new clinical trial data in this setting.
Together these agents are changing clinical practice and
making therapeutic decisions more complex. Here, we
discuss current and emerging therapeutic options for the
first-line treatment of advanced melanoma, and how these
therapies can be optimized to provide the best possible
outcomes for patients. Melanoma Res 00:000–000
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Introduction
In 2012, more than 100 000 people were diagnosed with
cutaneous melanoma in Europe and 22 200 people died
from the disease, making it the most deadly form of skin
cancer [1]. Melanoma is also the second most common
type of cancer in individuals aged 15–29 years [2]. Given
the high incidence rates among young adults and the
large number of deaths, melanoma has the potential to
result in many years of lost productivity and life [3]. The
prognosis for patients with stage III or IV disease has
historically been poor, with a median overall survival
(OS) of 6–9 months and a 5-year survival rate of less than
5% [4].
Before 2011, palliative surgery and/or radiotherapy, sys-
temic chemotherapy (typically dacarbazine, fotemustine,
or temozolomide), and/or immunotherapy with
interleukin-2 (IL-2) were the only therapeutic options for
patients with unresectable or metastatic disease [5–8]. As
none of the systemic treatment options had a proven
effect on OS, they were considered primarily palliative,
and European guidelines recommended that patients be
preferentially considered for entry into clinical trials of
investigational therapies [5–7,9]. The lack of approved
and effective first-line treatment options, together with
varying access to clinical trials, meant clinicians across
Europe often adopted different approaches to disease
management, relying on experimental regimens and
selecting chemotherapy-based regimens when no other
options were available [10].
Since 2011, however, a number of new agents (ipilim-
umab, vemurafenib, dabrafenib, trametinib, nivolumab,
and pembrolizumab) have been approved by the
European Medicines Agency (EMA) for the treatment of
patients with advanced melanoma [11–16]. These agents
have already changed clinical practice. In 2014, nivolu-
mab and pembrolizumab were approved in the USA as
second-line therapies, although studies for first-line use
(e.g. CheckMate 066, CheckMate 067, CheckMate 069,
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KEYNOTE-006) have led to their recent approval in
Europe for first-line treatment of patients with advanced
melanoma, regardless of BRAF status. With the avail-
ability of more therapeutic options, treatment decisions
are becoming more complex. Now it is not just a case of
making do with what is available, but ensuring that the
right treatment is provided to the right patient at the right
time. In this review, we consider the treatment options
that are now available and provide our opinions on how
these different agents should be used to maximize
patient outcomes and protect some of the years of life
that might previously have been lost.
Current first-line treatment options for
patients with advanced melanoma in Europe
Targeted therapy
Around 40–50% of melanomas harbor a BRAF-activating
mutation, 90% of which are at codon 600 [17]. The most
common mutation at codon 600 is a replacement of valine
with glutamic acid (V600E), accounting for up to 90% of
BRAF mutations at this location; however, many other
mutations exist [18].
Vemurafenib (Zelboraf; Roche/Genentech, San Francisco,
California, USA) and dabrafenib (Tafinlar; GlaxoSmithKline,
Research Triangle Park, North Carolina, USA) are selective
inhibitors that preferentially bind to mutant BRAF proteins.
Clinical trials have demonstrated rapid responses in many
patients treated with vemurafenib or dabrafenib, providing
symptomatic relief, prolonged progression-free survival (PFS),
and improved median OS, regardless of the line of treatment
[19–24]. In first-line registrational trials, median OS with
vemurafenib or dabrafenib was longer than previously
observed with chemotherapy [20–22]. In the phase 3 rando-
mized clinical trial, BRIM-3, median OS was 13.6 months
with vemurafenib and 9.7 months with dacarbazine in patients
with previously untreated BRAF V600E-positive metastatic
melanoma [20]. In the phase 3 randomized cross-over trial
BREAK-3, which allowed treatment beyond progression,
median OSwas 18.2 months with dabrafenib and 15.6 months
with dacarbazine in patients with BRAF V600E-positive
metastatic melanoma [22]. The efficacy of vemurafenib is
being evaluated in the setting of brain metastasis with
melanoma in phase 2 trials (NCT01378975; NCT01781026).
Like other targeted therapies, BRAF inhibitors are asso-
ciated with a predictable pattern of adverse events (AEs),
including skin toxicities such as rash, hyperkeratosis, cuta-
neous squamous cell carcinoma, keratoacanthoma, fatigue,
and pyrexia, as well as rare events such as uveitis and
Stevens–Johnson syndrome [17,25–28]. Both vemurafenib
and dabrafenib have been approved by the EMA for the
treatment of adult patients with BRAF V600 mutation-
positive unresectable or metastatic melanoma [12,13].
Preclinical data suggest that BRAF inhibitors are less
effective in melanoma cell lines with rare mutations [29];
however, limited clinical evidence suggests that these
agents have activity in V600R patients [30,31]. Further
research on the optimal treatment of non-V600E BRAF
melanoma patients is required.
When deciding between BRAF inhibitors for the treat-
ment of BRAF V600 mutation-positive advanced
melanoma, vemurafenib and dabrafenib appear to have
similar efficacy, and data for each confirm intracranial
activity and activity in patients with the V600K mutation
[32–35]. Dabrafenib appears to be associated with less
skin toxicity than vemurafenib; for example, in phase 3
trials, cutaneous squamous cell carcinomas were reported
in 19% of patients treated with vemurafenib compared
with 5% of patients receiving dabrafenib; ultraviolet-
dependent photosensitivity reactions also appear to be
more commonly reported with vemurafenib (41%) com-
pared with dabrafenib (2%) [19–21,36]. By contrast,
vemurafenib is associated with a lower incidence of
pyrexia and palmar–plantar erythrodysesthesia, which are
common AEs with dabrafenib [25,37].
One drawback to targeted therapy in advanced melanoma is
that, in most cases, patients will eventually develop drug
resistance [38]. Resistance to BRAF inhibitors and patient
relapse are common, ultimately affecting the potential for
long-term survival [39]. While multiple mechanisms of
resistance can bypass chronic BRAF inhibition, the pre-
dominant pattern of resistance involves BRAF-independent
reactivation of the mitogen-activated protein kinase (MAPK)
pathway. However, MAPK pathway-independent mechan-
isms may also play a potential role [40,41]. Patients typically
remain free from progression for a median of 7 months [19,
21], and as resistance is more likely to occur the duration of
benefit can be limited.
Besides BRAF inhibitors, the MEK inhibitor trametinib
(Mekinist; GlaxoSmithKline) has demonstrated activity
in patients with BRAF-positive metastatic melanoma,
and has recently been approved in Europe. Activated
BRAF phosphorylates and activates MEK proteins
(MEK1 and MEK2) and downstream MAPKs, which
regulate proliferation and survival of tumor cells [42]. In a
randomized phase 3 trial, trametinib improved rates of
PFS and OS compared with chemotherapy. The most
commonly reported AEs with trametinib were rash,
diarrhea, peripheral edema, and papulopustular derma-
titis, an on-target reaction pattern of the epidermis. No
secondary skin neoplasms were found [42,43].
Ongoing clinical studies suggest that coinhibition of MEK
and BRAF could potentially attenuate the development of
resistance to BRAF inhibition. Final results of the phase 3
COMBI-d trial comparing dabrafenib 150mg plus trameti-
nib 2mg versus dabrafenib plus placebo in patients with
BRAF V600E/K-mutant metastatic melanoma have been
reported [44]. The combination of dabrafenib plus trameti-
nib versus dabrafenib alone demonstrated a 33% reduction
in the risk of progression (P<0.001) and a 29% reduction in
the risk of death (median OS, 25.1 vs. 18.7 months;
P=0.011). Interim results of the phase 3 MEK115306
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demonstrated that the combination reduced risk of pro-
gression by 25% and improved response rate compared with
dabrafenib alone (67 vs. 51%), although a specified stopping
boundary for OS was not crossed [45]. Interim results from
the phase 3 COMBI-v trial showed an OS rate at 12 months
of 72% with the combination and 65% with vemurafenib. In
this case, the prespecified interim stopping boundary was
crossed, and the study was stopped [46]. In addition, the
phase 3 coBRIM trial of the investigational MEK inhib-
itor cobimetinib in combination with vemurafenib demon-
strated improvement in PFS compared with vemurafenib
alone (9.9 vs. 6.2 months, respectively) [47]. Updated results
for BRF113220, a phase I/II study of dabrafenib alone ver-
sus combined dabrafenib and trametinib in patients with
BRAF V600 metastatic melanoma, showed 2-year OS rates
of 44% with dabrafenib monotherapy and 51% with dabra-
fenib 150mg plus trametinib 2mg [48].
However, the combination appears to have limited effi-
cacy in patients who are already resistant to BRAF inhib-
itors, and the safety profile of the combination appears to
differ from the monotherapy [49,50]. Interestingly,
MEK-resistant BRAF-mutant advanced melanoma still
responds to BRAF inhibitor therapy, whereas BRAF
inhibitor-resistant melanoma does not respond to MEK
inhibitor therapy [51].
Immuno-oncology
The therapeutic potential of immunotherapy in melan-
oma was initially highlighted in studies investigating
activation of the immune system with the cytokines
interferon-α2b and IL-2 [52]. In the metastatic setting,
high-dose IL-2 was approved following results from
phase 1/2 studies reporting response rates of 10–20%,
with 4–6% of patients achieving a durable complete
remission [52]. However, high-dose IL-2 has not been
shown to improve OS [53], is not suitable for patients
with poor performance status, and may be associated with
the development of depression [52].
Ipilimumab is a monoclonal antibody that harnesses the
immune system by blocking cytotoxic T-lymphocyte-
associated antigen-4, an immune checkpoint that nega-
tively regulates T-cell activation. Ipilimumab was the
first agent to significantly improve survival compared
with control in randomized phase 3 trials of patients with
advanced melanoma, irrespective of mutation status [54,
55]. In 2011, ipilimumab 3mg/kg, administered intraven-
ously every 3 weeks for a total of four doses, received
European Union approval for the treatment of adult
patients with advanced melanoma who had received prior
therapy. Although the approved indication in the USA
was broader than in Europe (including patients irre-
spective of whether or not they had received prior ther-
apy) [56], the European indication for ipilimumab was
extended in 2013 to include first-line treatment [11].
Moreover, the National Institute for Health and Care
Excellence in the UK proposed that treatment
recommendations be extended to include ipilimumab as
an option for first-line advanced melanoma [57]. The
decision to expand the use of ipilimumab to treatment-
naive patients was based upon multiple data sets,
including pooled data from chemotherapy-naive patients
who were treated with ipilimumab 3mg/kg in one of four
clinical trials, as well as data from patients who received
commercially available ipilimumab in the USA who were
identified for inclusion in two separate observational
studies, providing important insights from the real-world
setting [11,58–60].
The pooled analysis of chemotherapy-naive patients was
conducted on the basis that chemotherapies were the
only agents approved for previously untreated patients
with advanced melanoma in Europe that were not
restricted by tumor genotype. With a median follow-up of
11.6 months, median OS for the 78 chemotherapy-naive
patients was 13.5 months, and 54, 32, and 24% of patients
were alive 1, 2, and 3 years after treatment initiation,
respectively [58].
In the two US observational studies (CA184-338 and
CA184-332) with at least 12 months’ follow-up since
starting treatment with ipilimumab 3mg/kg, median OS
was 14.5 months (n= 273) and 11.5 months (n= 157),
with 1-year survival rates of 59.2 and 46.7%, respectively
[59,60]. These populations represent ‘real-world’
patients, including elderly patients and those with
BRAF-mutated melanoma, brain metastases, and poor
performance status [59,60]. As may be expected with any
therapy, exploratory OS analyses of subgroups in CA184-
338 showed higher OS for patients with Eastern
Cooperative Oncology Group performance status (ECOG
PS) 0 vs. 1 (21.5 vs. 12.8 months), without brain metas-
tases (17.5 vs. 14.5 months, overall), and with a cutaneous
primary site (16.8 months) [59].
As ipilimumab targets the immune system rather than
directly targeting the tumor, this agent can be associated
with immune-related AEs, such as skin toxicity, colitis
(characterized by mild-to-moderate, but occasionally also
severe diarrhea), hypophysitis, and hepatitis. AEs asso-
ciated with ipilimumab are generally manageable by
trained physicians using established guidelines that
emphasize vigilance and prompt intervention, and the
safety profile of ipilimumab is consistent among
chemotherapy-naive, treatment-naive, and pretreated
patients [11,61].
Treatment with ipilimumab can provide patients with
durable tumor control and long-term survival benefits,
and the Society for Immunotherapy of Cancer treatment
recommendations include ipilimumab as an option for a
range of patients with stage IV melanoma, including
those with or without BRAF mutations and those with
KIT mutations [52]. Clinical trial and real-world data
suggest that treatment with ipilimumab may result in
long-term survival (>2 years) [8,54,59,60,62–66]. Data
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from a pooled analysis of 1861 patients who received ipili-
mumab at different dosing schedules and lines of therapy
across 12 prospective or retrospective studies showed 3-year
survival rates of 22% and a plateau effect for a number of
years, with a follow-up of 10 years [67]. When an additional
2985 patients treated as part of an expanded access program
were included, the 3-year survival rate was 21% and the
plateau in survival curves was maintained [67]. It is impor-
tant to note that because of the unique patterns of response
observed with ipilimumab, which are related to its immune-
mediated mechanism of action, patients with durable stable
disease or evidence of initial disease progression may
eventually respond and also achieve prolonged survival [68].
Because of a delayed time to response, tumor kinetics
should also be taken into consideration when treating
with ipilimumab. Multiple controlled studies of immuno-
oncology agents have shown a delayed separation in
survival curves, suggesting that patients destined to die
before the separation (i.e. within the first 3–6 months of
treatment) may not benefit from ipilimumab. An
exploratory analysis from the phase 3 MDX010-20 trial
found enhanced treatment efficacy for patients with
pretreated, advanced melanoma if they survived more
than 12 weeks from randomization, perhaps because this
increased the opportunity for patients to complete and
potentially benefit from all four doses of ipilimumab [69].
The first-line use of new immuno-oncology agents has
recently become possible, and combination of ipilimumab
with these new agents may become an option for advanced
melanoma in the near future. Programmed death-1 (PD-1)
is an inhibitory receptor expressed by activated T cells that
downmodulates effector functions [70]. Nivolumab
(Opdivo; Bristol-Myers Squibb, Princeton, New Jersey,
USA) and pembrolizumab (Keytruda; Merck, Kenilworth,
New Jersey, USA) are monoclonal antibodies that block
PD-1 to stimulate antitumor immune responses [15,16]. In
2014, both agents were approved in the USA in patients
who progress after treatment on ipilimumab and, if BRAF
V600 mutation-positive, a BRAF inhibitor, and nivolumab
was approved in Japan for unresectable melanoma.
Additional trials of these agents for first-line use are either
ongoing or have recently been completed.
In CheckMate 066, a phase 3 trial in patients with pre-
viously untreated metastatic melanoma without a BRAF
mutation, 1-year OS was 72.9% for nivolumab versus
42.1% with dacarbazine [objective response rates (ORRs)
were 40.0 vs. 13.9%, respectively] [71]. KEYNOTE-006,
a randomized, phase 3 study comparing pembrolizumab
(10 mg/kg every 2 or 3 weeks) with ipilimumab, met its
coprimary endpoints of PFS and OS and was stopped
early [72]. Approximately two-thirds of enrolled patients
had not received prior systemic therapy. Overall,
6-month PFS rates were 47.3, 46.4, and 26.5% for pem-
brolizumab every 2 or 3 weeks, and ipilimumab, with
estimated 1-year survival rates of 74.1, 68.4, and 58.2%,
respectively. Incidence of treatment-related grade 3–5
AEs was lower with pembrolizumab, at either dose, than
with ipilimumab, and no new safety concerns were
reported [72].
Results from CheckMate 069, a phase 2, randomized trial
of nivolumab in combination with ipilimumab versus
ipilimumab alone in patients with previously untreated,
advanced melanoma have recently been published [73].
ORR and PFS were significantly greater with combin-
ation therapy compared with ipilimumab alone. ORR
among patients with BRAF V600 wild-type tumors (the
primary endpoint) was significantly higher in the com-
bination group (61%) than in the ipilimumab mono-
therapy group (11%; P< 0.001). Median PFS was not
reached with combination therapy and was 4.4 months
with ipilimumab. Similar efficacy results were observed
in patients with BRAF mutation-positive tumors.
The safety observed in this study was consistent with
previous experience with the combination. The propor-
tion of patients with treatment-related grade 3 or 4 AEs
was higher in the combination group (54%) than with
ipilimumab (24%); however, most patients who experi-
enced such events (with the exception of endocrino-
pathies) had complete resolution with the use of
established safety guidelines. Treatment-related grade 3
or 4 AEs led to discontinuation of treatment in 38% of the
combination group and in 13% of the ipilimumab group.
The three deaths reported in the combination group
were linked to pre-existing conditions [73].
CheckMate 067 was the first phase 3 trial to evaluate the
combination of immune checkpoint inhibitors in any
tumor type, wherein treatment-naive patients received
either nivolumab in combination with ipilimumab or each
as monotherapy [74]. The coprimary endpoint of PFS
was reported as patients continued to be followed up for
OS at the time of this publication. Nivolumab, either in
combination with ipilimumab (11.5 months) or alone
(6.9 months), significantly improved PFS versus ipilim-
umab alone (2.9 months). Investigator-assessed ORR by
Response Evaluation Criteria in Solid Tumors v1.1 was
also higher in both the combination and nivolumab
monotherapy groups versus ipilimumab alone (57.6, 43.7,
and 19.0%, respectively; P< 0.001 for both combination
and nivolumab versus ipilimumab).
Treatment with the combination resulted in similar PFS
among patients with a BRAF mutation (11.7 months) and
in those with wild-type BRAF (11.2 months). Among
nivolumab groups, PFS was the same in patients with
PD-L1-positive tumors (14.0 months). However, in
patients with tumors negative for PD-L1, the combin-
ation conferred a numerical PFS improvement compared
with nivolumab alone (11.2 vs. 5.3 months). In contrast to
the PFS results, the combination resulted in a numer-
ically higher ORR compared with nivolumab or ipilim-
umab alone regardless of PD-L1 status. Among those
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with PD-L1-positive tumors, ORR was 72.1% for the
combination, 57.5% for nivolumab, and 21.3% for ipili-
mumab alone. In patients with PD-L1-negative tumors,
ORR was 54.8, 41.3, and 17.8%, respectively.
Although grade 3 or 4 AEs were generally higher in the
combination group than with nivolumab or ipilimumab
alone (55.0, 16.3, 27.3%, respectively), the safety profile
of the combination was consistent with earlier experience
and no new safety signals were identified, except that
more patients had multiple toxicities. Most select
(immune-mediated) AEs were managed and resolved
with established safety guidelines. There was one
treatment-related death in each monotherapy group, but
there were none in the combination group [74].
Following a positive opinion from the Committee for
Medicinal Products for Human Use, EU approval of
nivolumab monotherapy for first-line/second-line treat-
ment of advanced melanoma was announced in June
2015 [75]. On the basis of the demonstrated efficacy and
manageable safety profile by trained physicians in clinical
trials, the combination of nivolumab and ipilimumab
shows promise for the future management of patients
with advanced melanoma as a first-line therapy. The
need to evaluate patients by PD-L1 status for combina-
tion therapy remains to be determined.
Chemotherapy
Dacarbazine was first approved by the US Food and
Drug Administration in 1975, and despite never having
demonstrated an OS benefit versus no treatment has
served as the global ‘reference therapy’ used in random-
ized melanoma trials [76]. Dacarbazine is associated with
a relatively modest response rate of ∼ 5–15% and median
duration of response of 1.5–4 months, and has not
demonstrated a survival benefit versus best supportive
care [20,77,78]. On the basis of recent trials in previously
untreated, advanced melanoma, a median OS of
∼ 9 months and a 1-year OS rate of ∼ 36% represent the
upper boundary of historical benchmarks for dacarbazine
monotherapy [52,79–85].
Other cytotoxic compounds, including temozolomide,
cisplatin and carboplatin, vinca alkaloids, taxanes, and
nitrosoureas (e.g. fotemustine), have been investigated,
but none have significantly improved outcomes com-
pared with dacarbazine. Fotemustine has been approved
by some European regulators and is often used in
patients with melanoma metastatic to the brain because
of its potential enhanced ability to cross the blood–brain
barrier compared with dacarbazine [81,86]. Whether the
addition of fotemustine to dacarbazine can delay the
occurrence of brain metastases is unclear [85].
Integration of approved, first-line agents into
clinical practice
At present, when a patient with advanced melanoma
attends a clinic for the first time, there are a number of
treatment options to consider. As treatment decisions
become increasingly complex, guidelines are becoming
more pragmatic, considering the mechanism of action of
the treatments, the individual patient and tumor char-
acteristics, and the treatment goals (Fig. 1) [9]. While our
discussion will focus on currently approved treatment
options, it must not be forgotten that clinical trials should
be considered for all patients with advanced melanoma,
because a cure for all patients is still far away.
With more therapeutic options available for metastatic
melanoma, it is important that treatment be tailored
toward the individual. For example, patient character-
istics, such as rate of progression and extent of tumor
burden, should be considered when making treatment
decisions. For patients with rapid tumor kinetics, a rapid
reduction in symptoms is likely to be most important and
buys time for potentially effective second-line treatments
in parallel. If patients are symptomatic, a rapid reduction
in tumor volume can translate into benefits in quality of
life more or less immediately. By contrast, for patients
with slowly progressing disease or a lower tumor burden,
the goal of treatment should be long-term control of the
disease. These differing goals will affect which treatment
is the most suitable first-line option for individual
patients. It is also important to note that, to date, no
methodology for defining ‘progression or disease kinet-
ics’ has been accepted.
Ipilimumab and selective BRAF inhibitors are replacing
chemotherapy as first-line treatment options for patients
with advanced melanoma. In addition, the German
treatment guidelines pre-empted the EMA by suggesting
that ipilimumab is an appropriate first-line treatment
option for patients, irrespective of mutation status,
although patients who survive long enough to receive the
full course of treatment are likely to gain the most benefit
(Fig. 1) [9]. For patients with a BRAF mutation who are
unsuitable for treatment with ipilimumab (i.e. those who
are symptomatic or have rapidly progressing disease), the
choice is vemurafenib or dabrafenib. Currently, there is
not enough guidance to choose between vemurafenib
and dabrafenib. Disease kinetics, tumor burden, and, in
BRAF-mutated patients specifically, the potential for
post-treatment pattern of progression should also be
considered [87,88]. Treating physicians currently have to
make, at least in part, a ‘gut decision’; however, the
summary provided in Table 1 may help guide treatment
choices.
The treatment of advanced melanoma has evolved
rapidly over the past 5 years, and will continue to evolve,
with new treatment approaches in advanced clinical
development. Until data from randomized trials are
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Fig. 1
Determine
BRAF/NRAS/cKIT
mutational status
BRAF negative
BRAF negative:
Clinical trial
Ipilimumab
Monochemotherapy
High tumor load;
rapid progressiona
Clinical trial
Monochemotherapy
(polychemotherapy)
Clinical trial
Polychemotherapy
Best supportive care
Clinical trial
Monochemotherapy
Ipilimumab
Specific inhibitor
Clinical trial
Specific inhibitor
High tumor load;
rapid progressiona
Low tumor load;
slow progressiona
BRAF positive
BRAF positive:
Clinical trial
Specific inhibitor
Progression
Progression
Guidelines for the treatment of patients with advanced melanoma. aLife expectancy less than 12 weeks= rapidly progressing disease; more than
12 weeks= slowly progressing disease. Adapted with permission from Pflugfelder et al. [9].
Table 1 Summary of first-line treatment options available for use in Europe
Agents Notes
Vemurafenib or dabrafenib Associated with rapid responses, although duration of response is often limited because of the emergence of resistance; long-term benefit
unknown [19–22,39]
Unsuitable for patients with BRAF wild-type melanoma [12,13]
Recommended for use in patients with BRAF V600-mutated metastatic melanoma who have bulky, symptomatic disease, high tumor load,
and rapidly progressing disease [9,87]
Vemurafenib has demonstrated activity in patients with symptomatic and asymptomatic brain metastases [32]; dabrafenib has demonstrated
activity in patients with asymptomatic brain metastases [34]
Trametinib Significantly improved PFS and OS when compared with chemotherapy in a phase 3 trial [42,43]
Unsuitable for patients with BRAF wild-type melanomas
Efficacy in subpopulations remains to be demonstrated (e.g. patients with brain metastases)
Unlike BRAF inhibitors, trametinib is not associated with the development of cuSCC [42,43]
Ipilimumab Can provide patients with durable tumor control and long-term survival benefits, although responses to treatment can be delayed [63,64,67]
Recommended for use in patients with low tumor load and slowly progressing disease, regardless of mutational status; European guidelines
recommend use in patients with life expectancy of 3–4 months who should be able to receive the full course of treatment [6,7,9,87]
Demonstrated activity in patients with asymptomatic brain metastases [53]
Demonstrated activity in elderly patients and patients with mucosal and uveal melanoma in a European EAP [89–91]
Nivolumab Demonstrated survival benefit compared with dacarbazine in previously untreated melanoma without BRAF mutation [71]
Pembrolizumab Demonstrated survival benefit compared with ipilimumab in patients who were treatment-naive or received one previous systemic therapy for
advanced melanoma [72]
Dacarbazine Associated with a modest response rate; has never demonstrated a survival benefit [77,78]
Suitable for BRAF wild-type patients who cannot be considered for ipilimumab or a clinical trial
cuSCC, cutaneous squamous cell carcinomas; EAP, Expanded Access Programme; OS, overall survival; PFS, progression-free survival.
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available, recommendations based on the consensus of
experts, such as the Society for Immunotherapy of
Cancer, can provide guidance on optimal patient selec-
tion, sequencing of treatments, and ongoing patient
monitoring [52]. Furthermore, fruitful collaboration
between industry and healthcare professionals is needed
if we are to continue to support high-quality patient care.
Conclusion
The number of first-line options available for patients with
advanced melanoma is increasing, and treatment decisions
in melanoma are becoming ever more complex. Targeted
therapies have demonstrated prolonged PFS and improved
OS in patients with untreated BRAF-mutant melanoma;
however, these agents are often associated with drug
resistance, which can limit clinical benefit and affect out-
comes. Patients may also benefit from treatment with ipi-
limumab, which can provide durable tumor control and
long-term survival. The recent approvals of anti-PD-1
agents, as well as promising results from the combination
of nivolumab and ipilimumab, will potentially offer more
first-line options to clinicians to treat patients with
advanced melanoma. The changing landscape underlines
the importance of optimal treatment selection to maximize
the best possible outcomes for patients with advanced
melanoma.
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